Experienced in Vaginal Bleeding Between Periods

Dr. Andrew E. Green

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Lsu Health Sciences Center Shreveport Faculty Group Practice
1606 Kings Hwy, 
Shreveport, LA 
Accepting New Patients
Offers Telehealth
Experienced in Vaginal Bleeding Between Periods
Lsu Health Sciences Center Shreveport Faculty Group Practice
1606 Kings Hwy, 
Shreveport, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Green is a Gynecologic Oncologist and an Oncologist in Shreveport, Louisiana. Dr. Green is rated as an Experienced provider by MediFind in the treatment of Vaginal Bleeding Between Periods. His top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Cancer, Ovarian Cancer, Oophorectomy, and Hernia Surgery. Dr. Green is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in LA
Hospital Affiliations
Northeast Georgia Medical Center, Inc
Ochsner Lsu Health Shreveport-St Mary Medical Cent
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

LSU HEALTH SCIENCES CENTER SHREVEPORT FACULTY GROUP PRACTICE
1606 Kings Hwy, Shreveport, LA 71103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Enrollment Status: Unknown
Publish Date: February 19, 2018
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

Strategic multidisciplinary management of pelvic carcinosarcoma: Emphasizing advanced diagnostic imaging and staged surgical interventions.
Strategic multidisciplinary management of pelvic carcinosarcoma: Emphasizing advanced diagnostic imaging and staged surgical interventions.
Journal: Radiology case reports
Published: June 24, 2024
Similar Doctors
Distinguished in Vaginal Bleeding Between Periods
Dr. Andrew Galffy
Obstetrics and Gynecology
Distinguished in Vaginal Bleeding Between Periods
Dr. Andrew Galffy
Obstetrics and Gynecology

Christus Trinity Clinic

323 E Hawkins Pkwy, 
Longview, TX 
 (57.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Galffy is an Obstetrics and Gynecologist in Longview, Texas. Dr. Galffy is rated as an Advanced provider by MediFind in the treatment of Vaginal Bleeding Between Periods. His top areas of expertise are Vaginal Bleeding Between Periods, Adenomyosis, Painful Menstrual Periods, Intrauterine Device Insertion, and Oophorectomy. Dr. Galffy is currently accepting new patients.

Advanced in Vaginal Bleeding Between Periods
Dr. Maria C. Bellmann
Obstetrics and Gynecology
Advanced in Vaginal Bleeding Between Periods
Dr. Maria C. Bellmann
Obstetrics and Gynecology

Wk Doctors For Women

8001 Youree Dr, Suite 900, 
Shreveport, LA 
 (4.7 miles away)
318-797-0101
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Maria Bellmann is an Obstetrics and Gynecologist in Shreveport, Louisiana. Dr. Bellmann is rated as an Advanced provider by MediFind in the treatment of Vaginal Bleeding Between Periods. Her top areas of expertise are Pelvic Congestion Syndrome, Hydrocele, Vaginal Bleeding Between Periods, Angiomyoma, and Intrauterine Device Insertion. Dr. Bellmann is currently accepting new patients.

Advanced in Vaginal Bleeding Between Periods
Dr. Hollie B. Mccart
Obstetrics and Gynecology
Advanced in Vaginal Bleeding Between Periods
Dr. Hollie B. Mccart
Obstetrics and Gynecology

Wk Pierremont Ob-Gyn Specialists

8001 Youree Dr, Suite 600, 
Shreveport, LA 
 (4.7 miles away)
318-212-3890
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Hollie Mccart is an Obstetrics and Gynecologist in Shreveport, Louisiana. Dr. Mccart is rated as an Advanced provider by MediFind in the treatment of Vaginal Bleeding Between Periods. Her top areas of expertise are Amenorrhea, Painful Menstrual Periods, Vaginal Bleeding Between Periods, Menorrhagia, and Intrauterine Device Insertion. Dr. Mccart is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Green's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile